We are monitoring the impact of COVID-19 on APAC Hemophilia Management Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 273
Share on
Share on

Asia Pacific Hemophilia Management Market Research Report – Segmented By Type, Drug & By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) – Analysis on Size, Share, Trends, Growth, Forecasts (2020 to 2025)

Pulished: February, 2020
ID: 273
Pages: 139

APAC Hemophilia Management Market Size & Growth (2020 to 2025)

As per the report, the size of the Hemophilia Management Market in the Asia Pacific was worth USD 1020 million in 2020 and estimated to be growing at a CAGR of 1.78%, worth USD 1110 million by 2025.

Hemophilia is characterized into three levels depending upon its severity as severe, moderate and mild. Around 80% of the patients suffering from hemophilia are considered to be severe. The worldwide incidence of hemophilia is estimated at more than 400,000 people.

Asia-Pacific Hemophilia Management market is driven by factors such as the growing prevalence of the disease and the increasing usage of recombinant products. Advancements in technology and rising investments into Research and developments are also fuelling market growth.

However, lack of awareness about the disease and limited access to the medication are the key factors hindering the market growth. Advancements in gene therapy which help in the treatment of hemophilia also provide immense growth opportunities.

This research report on the APAC Hemophilia Management Market is segmented and sub-segmented into the following categories:

By Type:

  • Hemophilia A
  • Hemophilia B

By Drug:

  • Octocogalfa
  • Nonacogalfa
  • Desmopressin
  • Other Drugs

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, the Asia-Pacific region is estimated to be the fastest-growing region owing to its high population base and increasing healthcare expenditure. Within Asia-Pacific, Japan is a major market for hemophilia management due to high government support and widespread awareness about the treatment options for hemophilia. India is estimated to grow at the highest CAGR due to increasing incidence of hemophilia.

Noteworthy companies in the APAC Hemophilia Management Market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 BY Type                                        

                                5.1.1 Hemophilia A                         

                                5.1.2 Hemophilia B                          

                5.2 By Drug                                        

                                5.2.1 Octocogalfa                            

                                5.2.2 Nonacogalfa                           

                                5.2.3 Desmopressin                       

                                5.2.4 Other drugs                            

  1. Geographical Analysis

                6.3 Asia-Pacific                                 

                                6.1 Introduction                               

                                6.2 China                             

                                6.3 India                              

                                6.4 Japan                            

                                6.5 South Korea                               

                                6.6 Australia                      

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Biogen                                          

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Baxter International Inc.                                       

                8.4 Bayer Pharma AG                                    

                8.5 Novo Nordisk A/S                                    

                8.6 Grifols International SA                                         

                8.7 CSL Behring                                

                8.8 Octapharma                                               

                8.9 Swedish Orphan Biovitrum AB                                           

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

    Appendix                                                          

a) List of Tables

b) List of Figures

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Hemophilia Management Market By Region, From 2020 to 2025 (USD Million)
  2. Asia-Pacific Hemophilia Management Market By Type, From 2020 to 2025 (USD Million)
  3. Asia-Pacific Hemophilia-A Market By Region, From 2020 to 2025 (USD Million)
  4. Asia-Pacific Hemophilia-B Market By Region, From 2020 to 2025 (USD Million)
  5. Asia-Pacific Hemophilia Management Market By Drug, From 2020 to 2025 (USD Million)
  6. Asia-Pacific Octocogalfa Market By Region, From 2020 to 2025 (USD Million)
  7. Asia-Pacific Nonacogalfa Market By Region, From 2020 to 2025 (USD Million)
  8. Asia-Pacific Desmopressin Market By Region, From 2020 to 2025 (USD Million)
  9. Asia-Pacific Other drugs Market By Region, From 2020 to 2025 (USD Million)
  10. China Hemophilia Management Market By Type, From 2020 to 2025 (USD Million)
  11. China Hemophilia Management Market By Drug, From 2020 to 2025 (USD Million)
  12. India Hemophilia Management Market By Type, From 2020 to 2025 (USD Million)
  13. India Hemophilia Management Market By Drug, From 2020 to 2025 (USD Million)
  14. Japan Hemophilia Management Market By Type, From 2020 to 2025 (USD Million)
  15. Japan Hemophilia Management Market By Drug, From 2020 to 2025 (USD Million)
  16. South Korea Hemophilia Management Market By Type, From 2020 to 2025 (USD Million)
  17. South Korea Hemophilia Management Market By Drug, From 2020 to 2025 (USD Million)
  18. Australia Hemophilia Management Market By Type, From 2020 to 2025 (USD Million)
  19. Australia Hemophilia Management Market By Drug, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample